Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

WGS

GeneDx Holdings Corp

Sep 20 • 04:00PM ET

40.40

Dollar change -0.25
Percentage change -0.62	%

Healthcare • Health Information Services • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM VTI VXF IWN VTWO VFMO ITOT IWC CPAI AVSC

Index	RUT	P/E	-	EPS (ttm)	-4.50	Insider Own	30.14%	Shs Outstand	25.98M	Perf Week	6.68%
Market Cap	1.09B	Forward P/E	-	EPS next Y	-0.04	Insider Trans	-6.49%	Shs Float	18.82M	Perf Month	17.10%
Income	-117.47M	PEG	-	EPS next Q	-0.26	Inst Own	58.62%	Short Float	11.63%	Perf Quarter	47.12%
Sales	243.66M	P/S	4.47	EPS this Y	76.59%	Inst Trans	-11.56%	Short Ratio	5.12	Perf Half Y	340.09%
Book/sh	7.21	P/B	5.61	EPS next Y	96.55%	ROA	-27.15%	Short Interest	2.19M	Perf Year	963.16%
Cash/sh	3.97	P/C	10.19	EPS next 5Y	-	ROE	-47.93%	52W Range	1.16 - 40.92	Perf YTD	1369.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-38.26%	52W High	-1.27%	Beta	2.36
Dividend TTM	-	Quick Ratio	2.22	Sales past 5Y	5.08%	Gross Margin	47.32%	52W Low	3382.76%	ATR (14)	2.39
Dividend Ex-Date	-	Current Ratio	2.38	EPS Y/Y TTM	88.09%	Oper. Margin	-32.55%	RSI (14)	68.04	Volatility	6.13% 6.47%
Employees	1000	Debt/Eq	0.61	Sales Y/Y TTM	3.06%	Profit Margin	-48.21%	Recom	2.00	Target Price	40.83
Option/Short	Yes / Yes	LT Debt/Eq	0.58	EPS Q/Q	40.37%	Payout	-	Rel Volume	2.05	Prev Close	40.65
Sales Surprise	18.89%	EPS Surprise	70.10%	Sales Q/Q	44.77%	Earnings	Jul 30 AMC	Avg Volume	427.68K	Price	40.40
SMA20	16.13%	SMA50	20.47%	SMA200	132.11%	Trades		Volume	877,564	Change	-0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$34
Jul-10-24	Initiated	Craig Hallum	Buy	$43
Jun-03-24	Resumed	Jefferies	Hold	$21

Aug-12-24 04:05PM	GeneDx to Participate in Fall Investor Conferences (Business Wire)
Aug-09-24 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-30-24 08:57PM	WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) -10.57% +8.60%
04:05PM	GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
04:05PM	GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients (Business Wire)
12:00PM	Loading…
Jul-12-24 12:00PM	All You Need to Know About GENEDX HOLDINGS (WGS) Rating Upgrade to Strong Buy (Zacks)
Jul-11-24 04:05PM	GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024 (GlobeNewswire) +9.36%
Jul-06-24 07:00AM	7 Small-Cap Stocks With Massive Potential Returns (InvestorPlace)
Jun-10-24 08:30AM	GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients (GlobeNewswire)
Jun-05-24 07:00AM	GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients (GlobeNewswire) +13.20%
May-22-24 04:05PM	GeneDx to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-24 02:20PM	Hedge Fund and Insider Trading News: Michael Burry, Leon Cooperman, Ray Dalio, Stanley Druckenmiller, Millennium Management, Paulson & Co, Rokos Capital Management, Humacyte Inc (HUMA), GeneDx Holdings Corp. (WGS), and More (Insider Monkey) +13.52%
Apr-30-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +55.18%
Apr-29-24 08:55PM	WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:50PM	GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	GeneDx Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-23-24 08:30AM	GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset (GlobeNewswire) +15.50%
Apr-04-24 04:05PM	GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 (GlobeNewswire) +10.39%
Mar-21-24 09:55AM	Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher (Zacks) +7.87%
Mar-14-24 08:30AM	GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics (GlobeNewswire)
Feb-26-24 04:05PM	GeneDx to Participate in 44th Annual Cowen Health Care Conference (GlobeNewswire)
Feb-21-24 08:33AM	GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2023 Earnings Call Transcript (Insider Monkey) +32.63%
Feb-20-24 04:26PM	GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024 (GlobeNewswire)
Feb-01-24 04:30PM	GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 (GlobeNewswire)
Jan-24-24 04:30PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.98%
Jan-08-24 08:55AM	GeneDx Announces Preliminary 2023 Financial Results (GlobeNewswire) +40.36%
Dec-01-23 08:30AM	GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy (GlobeNewswire)
Nov-28-23 04:05PM	GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +12.80%
Nov-20-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -13.13%
Nov-10-23 09:55AM	Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now (Zacks) -13.61%
12:10PM	Loading…
Nov-05-23 12:10PM	GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 08:19AM	Q3 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents) -30.34%
Oct-30-23 06:02PM	GeneDx Holdings Corp (WGS) Reports Q3 2023 Financial Results (GuruFocus.com) -8.56%
04:05PM	GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-09-23 04:05PM	GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023 (GlobeNewswire)
Sep-22-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-23 01:01PM	Insider Sell: CEO Katherine Stueland Sells 2,675 Shares of GeneDx Holdings Corp (GuruFocus.com) -5.03%
Sep-11-23 08:00AM	GeneDx Announces Evolution of Executive Leadership Team (GlobeNewswire)
Sep-06-23 08:00AM	GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced (GlobeNewswire)
Aug-21-23 07:00AM	GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine (GlobeNewswire)
Aug-09-23 08:16AM	PacBio (PACB) Inks Research Collaboration for Genome Sequencing (Zacks) -12.63%
07:59AM	Q2 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 08:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-07-23 08:00AM	PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care (GlobeNewswire) -6.30%
Jul-19-23 07:05AM	GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options (GlobeNewswire) +6.48%
Jul-18-23 04:05PM	GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (GlobeNewswire)
Jun-28-23 07:00AM	GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundations Mitochondrial Medicine Symposium (GlobeNewswire) +11.53%
Jun-26-23 04:01PM	GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants (GlobeNewswire)
Jun-20-23 07:00AM	GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients (GlobeNewswire) -6.11%
May-24-23 04:05PM	GeneDx to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-23-23 07:00AM	GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations (GlobeNewswire)
May-22-23 04:05PM	GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +13.10%
May-15-23 09:35AM	Down -27.82% in 4 Weeks, Here's Why You Should You Buy the Dip in GeneDx Holdings Corp. (WGS) (Zacks)
May-09-23 04:05PM	GeneDx Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -5.65%
May-04-23 07:00AM	GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option (GlobeNewswire)
May-03-23 01:06PM	GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders (GlobeNewswire)
Apr-28-23 06:39PM	Why GeneDx Holdings Stock Lagged the Market Today (Motley Fool) -8.44%
08:10AM	GeneDx Announces Reverse Stock Split (GlobeNewswire)
07:04AM	Daily Vickers Top Buyers & Sellers for 04/28/2023 (Argus Research)
Apr-18-23 04:05PM	GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023 (GlobeNewswire)
12:55PM	Shareholders Should Be Pleased With GeneDx Holdings Corp.'s (NASDAQ:WGS) Price (Simply Wall St.)
Apr-03-23 08:30AM	GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel (GlobeNewswire)
Mar-22-23 04:36PM	Why Shares of GeneDx Dropped Wednesday (Motley Fool) -16.02% -13.95%
Mar-20-23 09:07PM	GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2022 Earnings Call Transcript (Insider Monkey) +41.30% -9.54%
08:45AM	GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease Diagnostic Odyssey (GlobeNewswire)
Mar-18-23 06:48PM	The 7 Worst Stocks to Buy Now (InvestorPlace)
Mar-16-23 08:45AM	GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray (GlobeNewswire)
Mar-14-23 04:16PM	GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-01-23 07:30AM	GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) -5.20%
Feb-28-23 08:30AM	GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting (GlobeNewswire)
Feb-21-23 04:30PM	GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023 (GlobeNewswire) -8.42%
Feb-16-23 08:30AM	GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases (GlobeNewswire) +5.82%
Jan-31-23 04:15PM	GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering (GlobeNewswire) +5.75% -9.44%
Jan-30-23 08:30AM	GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery (GlobeNewswire)
Jan-27-23 06:00AM	GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering (GlobeNewswire) +10.26%
Jan-26-23 04:53PM	GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering (GlobeNewswire)

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OPKO HEALTH, INC.	10% Owner	Sep 17 '24	Proposed Sale	40.88	13,404	547,956		Sep 20 02:56 PM
Stueland Katherine	Chief Executive Officer	Sep 16 '24	Option Exercise	0.00	18,750	0	114,207	Sep 18 04:28 PM
Stueland Katherine	Chief Executive Officer	Sep 16 '24	Sale	37.59	10,501	394,733	103,706	Sep 18 04:28 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 16 '24	Option Exercise	0.00	7,197	0	47,107	Sep 18 04:26 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 16 '24	Sale	37.59	2,635	99,050	44,472	Sep 18 04:26 PM
Kevin Feeley	Officer	Sep 16 '24	Proposed Sale	37.59	2,635	99,050		Sep 16 06:54 PM
Katherine Stueland	Director	Sep 16 '24	Proposed Sale	37.59	10,501	394,733		Sep 16 06:54 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '24	Option Exercise	0.00	2,462	0	40,805	Sep 11 08:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '24	Sale	33.33	895	29,830	39,910	Sep 11 08:14 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '24	Option Exercise	0.00	6,546	0	99,096	Sep 11 08:10 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '24	Sale	33.33	3,639	121,288	95,457	Sep 11 08:10 PM
Kevin Feeley	Officer	Sep 09 '24	Proposed Sale	33.33	895	29,830		Sep 09 09:03 PM
Katherine Stueland	Officer	Sep 09 '24	Proposed Sale	33.33	3,639	121,288		Sep 09 09:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 01 '24	Option Exercise	0.00	717	0	38,605	Sep 04 08:10 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 03 '24	Sale	31.71	262	8,308	38,343	Sep 04 08:10 PM
Kevin Feeley	Officer	Sep 03 '24	Proposed Sale	31.71	262	8,308		Sep 03 09:35 PM
OPKO HEALTH, INC.	10% Owner	Aug 19 '24	Sale	34.49	50,000	1,724,520	2,646,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 16 '24	Sale	34.30	50,000	1,714,850	2,696,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 15 '24	Sale	33.08	39,824	1,317,505	2,746,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 12 '24	Sale	33.95	59,787	2,029,811	2,811,783	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 13 '24	Sale	34.76	24,987	868,503	2,786,796	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 08 '24	Sale	31.82	100,000	3,182,380	2,871,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Aug 06 '24	Sale	29.35	12,994	381,427	2,971,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Jul 31 '24	Sale	33.50	88,839	2,976,346	2,984,564	Aug 02 04:21 PM
OPKO HEALTH, INC.	10% Owner	Jul 29 '24	Sale	33.86	50,000	1,692,890	3,073,403	Jul 31 05:03 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '24	Option Exercise	0.00	3,874	0	94,704	Jul 31 04:40 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '24	Sale	33.54	2,154	72,245	92,550	Jul 31 04:40 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Option Exercise	0.00	753	0	38,162	Jul 31 04:39 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Sale	33.54	274	9,190	37,888	Jul 31 04:39 PM
OPKO HEALTH, INC.	10% Owner	Jul 24 '24	Sale	33.72	75,000	2,529,105	3,183,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 26 '24	Sale	33.85	60,000	2,031,258	3,123,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 23 '24	Sale	33.46	75,000	2,509,245	3,258,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 22 '24	Sale	32.61	50,000	1,630,440	3,333,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 19 '24	Sale	32.29	25,000	807,250	3,383,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 17 '24	Sale	32.93	25,000	823,188	3,408,403	Jul 19 06:46 PM
OPKO HEALTH, INC.	10% Owner	Jul 05 '24	Sale	28.24	36,118	1,020,016	3,433,403	Jul 09 04:07 PM
OPKO HEALTH, INC.	10% Owner	Jul 01 '24	Sale	26.63	50,000	1,331,700	3,508,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 02 '24	Sale	29.12	25,000	728,095	3,483,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 03 '24	Sale	28.23	14,082	397,491	3,469,521	Jul 03 04:56 PM
Casdin Eli	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	7,593	Jun 24 07:04 PM
Leproust Emily M.	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	8,352	Jun 24 05:42 PM
PFENNIGER RICHARD C JR	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	27,664	Jun 24 05:41 PM
RUCH JOSHUA	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	7,853	Jun 24 05:40 PM
Meister Keith A.	Director	Jun 20 '24	Option Exercise	0.00	5,828	0	7,205	Jun 24 05:39 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 16 '24	Option Exercise	0.00	7,197	0	40,055	Jun 18 05:18 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 17 '24	Sale	28.31	2,646	74,908	37,409	Jun 18 05:18 PM
Stueland Katherine	Chief Executive Officer	Jun 16 '24	Option Exercise	0.00	18,750	0	98,513	Jun 18 05:17 PM
Stueland Katherine	Chief Executive Officer	Jun 17 '24	Sale	28.31	7,683	217,506	90,830	Jun 18 05:17 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 09 '24	Option Exercise	0.00	2,462	0	33,753	Jun 11 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 10 '24	Sale	24.92	895	22,303	32,858	Jun 11 04:14 PM
Stueland Katherine	Chief Executive Officer	Jun 09 '24	Option Exercise	0.00	6,546	0	82,415	Jun 11 04:13 PM
Stueland Katherine	Chief Executive Officer	Jun 10 '24	Sale	24.92	2,652	66,088	79,763	Jun 11 04:13 PM
Casdin Capital, LLC	Director	Jun 03 '24	Buy	20.82	100,000	2,081,640	3,063,509	Jun 05 08:45 PM
Casdin Capital, LLC	Director	Jun 04 '24	Buy	22.52	30,000	675,477	3,093,509	Jun 05 08:45 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 01 '24	Option Exercise	0.00	717	0	31,553	Jun 04 04:20 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 03 '24	Sale	20.55	262	5,384	31,291	Jun 04 04:20 PM
Casdin Capital, LLC	Director	May 29 '24	Buy	21.07	40,000	842,604	2,963,509	May 31 05:37 PM
Casdin Capital, LLC	Director	May 24 '24	Buy	20.12	144,196	2,900,906	2,905,205	May 28 08:40 PM
Casdin Capital, LLC	Director	May 28 '24	Buy	20.61	18,304	377,167	2,923,509	May 28 08:40 PM
Casdin Capital, LLC	Director	May 23 '24	Buy	19.59	7,500	146,916	2,761,009	May 28 08:40 PM
Casdin Capital, LLC	Director	May 13 '24	Buy	23.31	50,000	1,165,295	2,753,509	May 15 06:16 PM
PFENNIGER RICHARD C JR	Director	May 02 '24	Option Exercise	0.00	918	0	21,836	May 03 04:04 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '24	Option Exercise	0.00	15,496	0	82,194	Apr 30 04:30 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '24	Sale	11.04	6,325	69,808	75,869	Apr 30 04:30 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '24	Option Exercise	0.00	3,013	0	31,940	Apr 30 04:27 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '24	Sale	11.04	1,104	12,185	30,836	Apr 30 04:27 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 16 '24	Option Exercise	0.00	18,750	0	75,257	Mar 19 04:15 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 18 '24	Sale	10.59	8,559	90,661	66,698	Mar 19 04:15 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 16 '24	Option Exercise	0.00	5,114	0	31,525	Mar 19 04:14 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 18 '24	Sale	10.59	2,008	21,269	29,517	Mar 19 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 16 '24	Option Exercise	0.00	7,197	0	32,180	Mar 19 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 18 '24	Sale	10.59	3,253	34,455	28,927	Mar 19 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 12 '24	Sale	9.21	931	8,574	24,983	Mar 13 04:28 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 12 '24	Sale	9.21	2,618	24,111	56,507	Mar 13 04:24 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 12 '24	Sale	9.21	897	8,261	26,411	Mar 13 04:22 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 09 '24	Option Exercise	0.00	2,462	0	25,914	Mar 12 05:27 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 09 '24	Option Exercise	0.00	6,547	0	59,125	Mar 12 05:26 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 09 '24	Option Exercise	0.00	2,841	0	27,308	Mar 12 05:25 PM
Casdin Capital, LLC	Director	Mar 04 '24	Buy	8.74	40,000	349,708	2,702,609	Mar 06 07:32 PM
Casdin Capital, LLC	Director	Mar 05 '24	Buy	8.83	900	7,944	2,703,509	Mar 06 07:32 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Jan 19 '24	Option Exercise	0.00	546	0	24,660	Jan 23 04:10 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Jan 22 '24	Sale	3.24	193	625	24,467	Jan 23 04:10 PM
Saad Kareem	Chief Transformation Officer	Jan 03 '24	Sale	2.58	105	271	24,114	Jan 04 05:03 PM
Saad Kareem	Chief Transformation Officer	Jan 01 '24	Option Exercise	0.00	273	0	24,219	Jan 03 04:25 PM
Ryan Jason	Executive Chairman	Dec 31 '23	Option Exercise	0.00	67,780	0	73,614	Jan 03 04:23 PM
Stueland Katherine	Chief Executive Officer	Dec 16 '23	Option Exercise	0.00	18,750	0	64,312	Dec 19 09:26 PM
Stueland Katherine	Chief Executive Officer	Dec 18 '23	Sale	2.16	11,734	25,338	52,578	Dec 19 09:26 PM
Saad Kareem	Chief Transformation Officer	Dec 16 '23	Option Exercise	0.00	5,114	0	25,646	Dec 19 09:25 PM
Saad Kareem	Chief Transformation Officer	Dec 18 '23	Sale	2.16	1,700	3,671	23,946	Dec 19 09:25 PM
Feeley Kevin	Chief Financial Officer	Dec 16 '23	Option Exercise	0.00	7,197	0	25,983	Dec 19 09:24 PM
Feeley Kevin	Chief Financial Officer	Dec 18 '23	Sale	2.16	2,948	6,366	23,035	Dec 19 09:24 PM
Stueland Katherine	Chief Executive Officer	Dec 09 '23	Option Exercise	0.00	6,546	0	49,235	Dec 12 04:06 PM
Stueland Katherine	Chief Executive Officer	Dec 11 '23	Sale	1.61	3,673	5,915	45,562	Dec 12 04:06 PM
Saad Kareem	Chief Transformation Officer	Dec 09 '23	Option Exercise	0.00	2,841	0	21,382	Dec 12 04:05 PM
Saad Kareem	Chief Transformation Officer	Dec 11 '23	Sale	1.61	850	1,369	20,532	Dec 12 04:05 PM
Feeley Kevin	Chief Financial Officer	Dec 09 '23	Option Exercise	0.00	2,462	0	19,694	Dec 12 04:04 PM
Feeley Kevin	Chief Financial Officer	Dec 11 '23	Sale	1.61	908	1,462	18,786	Dec 12 04:04 PM
Feeley Kevin	Chief Financial Officer	Dec 04 '23	Sale	1.77	270	478	17,232	Dec 05 04:45 PM
Ryan Jason	Executive Chairman	Nov 17 '23	Buy	1.54	58,000	89,181	114,742	Nov 20 04:32 PM
Ryan Jason	Executive Chairman	Nov 16 '23	Buy	1.27	56,742	72,187	56,742	Nov 20 04:32 PM

Open in Screener

TSVT

2seventy bio Inc

Sep 20 • 04:00PM ET

5.05

Dollar change +0.18
Percentage change 3.70	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC PRFZ FESM

Index	RUT	P/E	-	EPS (ttm)	-3.06	Insider Own	6.38%	Shs Outstand	50.63M	Perf Week	7.22%
Market Cap	260.08M	Forward P/E	-	EPS next Y	-0.68	Insider Trans	32.59%	Shs Float	48.21M	Perf Month	6.99%
Income	-156.25M	PEG	-	EPS next Q	-0.27	Inst Own	92.62%	Short Float	12.34%	Perf Quarter	35.75%
Sales	44.12M	P/S	5.89	EPS this Y	79.16%	Inst Trans	-1.51%	Short Ratio	14.81	Perf Half Y	1.20%
Book/sh	4.56	P/B	1.11	EPS next Y	25.87%	ROA	-25.54%	Short Interest	5.95M	Perf Year	47.23%
Cash/sh	3.92	P/C	1.29	EPS next 5Y	-	ROE	-51.89%	52W Range	1.53 - 6.40	Perf YTD	18.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-33.20%	52W High	-21.09%	Beta	1.78
Dividend TTM	-	Quick Ratio	4.76	Sales past 5Y	73.45%	Gross Margin	41.90%	52W Low	228.99%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	4.76	EPS Y/Y TTM	28.72%	Oper. Margin	-421.88%	RSI (14)	63.81	Volatility	5.29% 6.35%
Employees	274	Debt/Eq	1.07	Sales Y/Y TTM	-70.04%	Profit Margin	-354.16%	Recom	3.00	Target Price	6.00
Option/Short	Yes / Yes	LT Debt/Eq	1.00	EPS Q/Q	154.77%	Payout	-	Rel Volume	2.16	Prev Close	4.87
Sales Surprise	-19.06%	EPS Surprise	167.59%	Sales Q/Q	-75.12%	Earnings	Aug 07 BMO	Avg Volume	401.82K	Price	5.05
SMA20	9.50%	SMA50	10.95%	SMA200	13.35%	Trades		Volume	867,643	Change	3.70%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-24	Downgrade	Goldman	Neutral → Sell	$5 → $2
Jan-31-24	Upgrade	Leerink Partners	Market Perform → Outperform	$5 → $18
Jan-31-24	Downgrade	TD Cowen	Outperform → Market Perform
Oct-30-23	Downgrade	Leerink Partners	Outperform → Market Perform	$6
Oct-12-23	Initiated	Citigroup	Buy	$13
Sep-13-23	Downgrade	Goldman	Buy → Neutral	$5
Sep-12-23	Downgrade	Guggenheim	Buy → Neutral
Jul-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$25 → $13
Oct-31-22	Initiated	Guggenheim	Buy	$30
May-02-22	Initiated	Goldman	Buy	$26
Feb-10-22	Initiated	SVB Leerink	Outperform	$38
Jan-06-22	Initiated	Cowen	Outperform
Nov-09-21	Initiated	Canaccord Genuity	Buy	$42
Nov-08-21	Initiated	Wedbush	Outperform
Nov-08-21	Initiated	Morgan Stanley	Overweight

Show Previous Ratings

Aug-29-24 07:00AM	2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference (Business Wire) +8.56%
Aug-07-24 07:00AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire) +8.21%
Aug-05-24 07:00AM	2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024 (Business Wire)
Jul-05-24 06:45AM	3 Hidden Stock Gems That Wall Street Is Overlooking (InvestorPlace)
Jun-26-24 04:11PM	2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million (Business Wire)
07:00AM	Loading…
May-23-24 07:00AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-08-24 11:57AM	TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace) -9.68%
08:15AM	2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire)
May-03-24 07:00AM	2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 (Business Wire)
Apr-24-24 10:01AM	2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.78%
Apr-17-24 11:02AM	2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why (Zacks)
Apr-05-24 09:05AM	U.S. FDA Approves Bristol Myers Squibb and 2seventy bios Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy (Business Wire)
Apr-01-24 07:30AM	2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron (Business Wire) +8.22%
05:04PM	Loading…
Mar-20-24 05:04PM	2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors (Business Wire) +9.91%
Mar-15-24 06:27PM	FDA Advisory Committee Votes in Favor of Bristol Myers Squibbs and 2seventy bios Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy (Business Wire)
Mar-07-24 09:10AM	2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.11%
Mar-05-24 07:53AM	TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +6.83%
07:00AM	2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress (Business Wire)
Mar-04-24 08:56AM	Should You Buy 2seventy bio (TSVT) Ahead of Earnings? (Zacks)
Mar-01-24 07:00AM	2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences (Business Wire) +8.46%
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile) +8.36%
Feb-05-24 04:05PM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire) +7.62%
06:59AM	Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study (Business Wire)
Feb-01-24 08:27AM	2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains? (Zacks)
Jan-31-24 11:11AM	2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up (Zacks) +28.18%
Jan-30-24 07:01AM	2seventy bio Announces New Strategic Path Forward (Business Wire) +14.90%
Jan-12-24 12:00PM	All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy (Zacks)
Dec-11-23 07:30PM	Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3 (Business Wire)
07:00AM	Loading…
07:00AM	2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel) (Business Wire)
Dec-06-23 02:00PM	2seventy bio Reiterates Commitment to Maximizing Shareholder Value (Business Wire) +9.30%
Nov-20-23 12:02PM	Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug (Investopedia) -18.31%
06:59AM	Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma (Business Wire)
Nov-14-23 07:00AM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire)
Nov-10-23 07:00AM	2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023 (Business Wire)
Sep-12-23 07:00AM	2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway (Business Wire) -5.02%
06:55AM	2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies (Business Wire)
Sep-06-23 07:00AM	2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-24-23 09:00PM	CFO Baird William D III Sells 7,031 Shares of 2seventy bio Inc (TSVT) (GuruFocus.com)
Aug-14-23 07:00AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire)
Aug-08-23 07:00AM	2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023 (Business Wire)
Aug-01-23 04:15PM	2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference (Business Wire) -8.56% -7.06%
Jun-14-23 07:00AM	2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia (Business Wire) -8.98%
Jun-07-23 07:00AM	2seventy bio to Participate in Upcoming Investor Conference (Business Wire)
May-19-23 06:00AM	2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (Business Wire)
May-17-23 07:17AM	2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio (Business Wire)
May-11-23 12:37PM	2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 (Business Wire)
May-03-23 04:05PM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire) +14.53%
May-02-23 04:37PM	2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting (Business Wire)
10:00AM	Billionaire Ken Griffin Doubles Down on These 2 Strong Buy Stocks Heres Why You Might Want to Follow in His Footsteps (TipRanks)
May-01-23 07:00AM	2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program (Business Wire) +8.31%
Apr-28-23 08:30AM	2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire) +5.78%
Apr-17-23 06:59AM	Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma (Business Wire)
Mar-16-23 04:05PM	2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress (Business Wire)
Mar-08-23 08:30AM	2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors (Business Wire)
Mar-03-23 07:00AM	2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference (Business Wire)
Mar-01-23 09:00AM	Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer (PR Newswire) -18.38%
Feb-28-23 09:00PM	2seventy bio Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
04:01PM	2seventy bio Announces Proposed Public Offering of Common Stock (Business Wire)
Feb-10-23 11:13AM	Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study (Business Wire)
Feb-01-23 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Jan-18-23 11:35AM	Medigene Receives $3 Million Milestone Payment from 2seventy bio (GlobeNewswire)
Jan-09-23 08:00AM	2seventy bio Provides Company Outlook for 2023 (Business Wire)
Jan-06-23 09:11AM	2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors (Business Wire)
Nov-07-22 04:05PM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire) +6.78%
Nov-03-22 09:06AM	2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-27-22 07:00AM	2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies (Business Wire)
Sep-07-22 07:00AM	2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients (Business Wire) +5.76%
Aug-31-22 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-22 06:23AM	2seventy bio, Inc. (NASDAQ:TSVT) Analysts Just Slashed This Year's Revenue Estimates By 12% (Simply Wall St.)
Aug-10-22 06:50AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire)
06:45AM	Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma (Business Wire)
Aug-04-22 07:02AM	Will 2seventy bio (NASDAQ:TSVT) Spend Its Cash Wisely? (Simply Wall St.)
Aug-03-22 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-04-22 03:30PM	A 2seventy bio, Inc. (NASDAQ:TSVT) insider increased their holdings by 251% last year (Simply Wall St.)
Jun-06-22 07:30AM	2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference (Business Wire)
May-12-22 04:05PM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire) +6.05%
May-04-22 09:10PM	Goldman Sachs Sees These 2 Strong Buy Stocks Skyrocketing Over 70% (TipRanks) +5.65% -7.53%
Apr-08-22 04:15PM	2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting (Business Wire)
Apr-07-22 07:30AM	2seventy bio to Participate in CG Horizons in Oncology Virtual Conference (Business Wire)
Mar-22-22 07:00AM	2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress (Business Wire) +5.28%
Mar-16-22 08:41AM	2seventy bio Secures $170 Million in Private Placement Equity Financing (Business Wire) +14.59%
Feb-14-22 07:30AM	2seventy bio Announces Key Management Appointments (Business Wire)
07:00AM	2seventy bio to Participate in Upcoming Healthcare Conferences (Business Wire)
Feb-11-22 09:58AM	Do Institutions Own 2seventy bio, Inc. (NASDAQ:TSVT) Shares? (Simply Wall St.) -5.84%
Feb-03-22 01:38PM	Virginia Retirement Systems Et Al Buys Wolfspeed Inc, Orion Office REIT Inc, Kyndryl Holdings ... (GuruFocus.com)
Jan-26-22 08:00AM	Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer (GlobeNewswire) -9.53%
Jan-11-22 07:00AM	2seventy bio Shares Key Milestones and Business Updates for 2022 (Business Wire)
Jan-06-22 07:00AM	2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach (Business Wire) +10.22%
Dec-13-21 06:15PM	2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting (Business Wire) +8.26% -10.32%
Dec-01-21 07:00AM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire)
Nov-15-21 10:43AM	Morgan Stanley: These 3 Strong Buy Stocks Could Surge at Least 60% (TipRanks)
Nov-10-21 04:30PM	2seventy bio to Present at the 5th Annual Cowen IO Next Summit (Business Wire) -5.08%

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Snow Jessica	See Remarks	Aug 14 '24	Sale	4.32	7,816	33,760	156,330	Aug 16 05:10 PM
JESSICA SNOW	Officer	Aug 14 '24	Proposed Sale	4.32	7,816	33,760		Aug 14 05:19 PM
Eatwell Victoria	Chief Financial Officer	Aug 05 '24	Sale	3.98	13	52	341,319	Aug 07 04:56 PM
Snow Jessica	See Remarks	Jul 02 '24	Sale	4.02	14	56	164,146	Jul 03 04:14 PM
Eatwell Victoria	Chief Financial Officer	Jul 02 '24	Sale	4.02	12	48	341,332	Jul 03 04:14 PM
Eatwell Victoria	Chief Financial Officer	Jun 03 '24	Sale	4.18	1,167	4,881	95,480	Jun 05 07:16 PM
Snow Jessica	See Remarks	Jun 03 '24	Sale	4.18	649	2,714	55,622	Jun 05 07:16 PM
Snow Jessica	See Remarks	May 03 '24	Sale	4.91	15	74	56,271	May 16 06:40 PM
Casdin Capital, LLC	Director	Mar 26 '24	Buy	5.10	40,000	203,992	2,000,000	Mar 28 08:29 PM
Casdin Capital, LLC	Director	Mar 25 '24	Buy	5.07	330,000	1,673,991	1,960,000	Mar 25 09:44 PM
Casdin Capital, LLC	Director	Mar 21 '24	Buy	4.90	300,000	1,470,990	1,482,623	Mar 25 09:44 PM
Casdin Capital, LLC	Director	Mar 22 '24	Buy	5.12	147,377	754,069	1,630,000	Mar 25 09:44 PM
Baird William D III	Chief Operating Officer	Jan 05 '24	Sale	3.75	1,380	5,180	161,335	Jan 09 04:09 PM
Gregory Philip D	Chief Scientific Officer	Jan 05 '24	Sale	3.75	795	2,984	230,842	Jan 09 04:09 PM
Leschly Nick	President and CEO	Jan 05 '24	Sale	3.75	1,554	5,833	1,085,476	Jan 09 04:08 PM
Leschly Nick	President and CEO	Jan 03 '24	Sale	3.87	72,312	279,739	1,087,030	Jan 05 04:30 PM
Gregory Philip D	Chief Scientific Officer	Jan 03 '24	Sale	3.87	25,613	99,084	231,637	Jan 05 04:30 PM
Baird William D III	Chief Operating Officer	Jan 03 '24	Sale	3.87	33,651	130,179	162,715	Jan 05 04:29 PM

WGS

GeneDx Holdings Corp

TSVT

2seventy bio Inc

Upgrade your FINVIZ experience